Alabama is currently home to 1237 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Birmingham, Mobile, Huntsville and Anniston. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Integrated e-Health (Electronic Health) for HIV and Substance Use Disorders in Justice Involved Women
NCT05547048
Recruiting
The purpose of this 2-site (CT, AL) study is to test innovative interventions to reduce stigma and improve the pre-exposure prophylaxis (PrEP) and opioid use disorder (OUD) care continua in women involved in the criminal justice system (WICJ). This study evaluates a newly validated PrEP decision aid and eHealth for integrated PrEP and MOUD compared to a decision aid-only for WICJ with OUD.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: University of Alabama in Birmingham, Birmingham, Alabama
Conditions: HIV, Opioid Use Disorder, eHealth
Register for Updates
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
NCT05429632
Recruiting
This is a multi-center, randomized, double-blinded, placebo controlled trial.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/13/2025
Locations: University of Alabama Hospital (UAB Hospital), Birmingham, Alabama
Conditions: Adult Acute Myeloid Leukemia
Register for Updates
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
NCT05272384
Recruiting
This phase I trial tests the safety, side effects, and best dose of nivolumab in combination with ASTX727 in treating B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. ASTX727 consists of the combination of decitabine and cedazuridine. Cedazuridine is in a class of medicat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Hodgkin Lymphoma
Register for Updates
Risk Underlying Rural Areas Longitudinal Cohort Study (RURAL) Heart and Lung Study
NCT05006729
Recruiting
The University of Texas Health Science Center at San Antonio (UTHSCSA) will serve as the site for the RURAL Study Coordinating Center, led by PI Vasan Ramachandran, MD. The primary function of the Study Coordinating Center (SCC) is to serve as an administrative liaison between all of the RURAL study's cores. The SCC schedules, facilitates, and hosts, all RURAL meetings including preparation for Observational Study Monitoring Board (OSMB) meetings, and maintains direct communication with the stu... Read More
Gender:
ALL
Ages:
Between 25 years and 64 years
Trial Updated:
05/13/2025
Locations: University of Alabama, Birmingham, Alabama
Conditions: Rural Health, Pulmonary Disease, Heart Diseases
Register for Updates
Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism
NCT04790370
Recruiting
There are many available treatments for pulmonary embolism (PE), but the best treatment for this condition is not known. The HI-PEITHO study will compare two treatment options that are both available on the market for the treatment of PE. Patients will be randomized 1:1 to receive either blood thinners (anticoagulation) or blood thinners (anticoagulation) in combination with a device called the EkoSonicTM Endovascular device to dissolve blood clots. Patients will be followed for 12 months after... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/13/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Pulmonary Embolism
Register for Updates
Influence of Obesity on Endogenous Oxalate Synthesis
NCT03704350
Recruiting
There is increasing evidence that obesity is associated with increased urinary oxalate excretion, an important risk factor for calcium oxalate stone formation. By the administration of a controlled low oxalate diet the investigators will estimate endogenous oxalate synthesis in both non-obese and obese non-kidney-stone forming adults. This study seeks to thusly increase the understanding of the relationships between obesity and endogenous oxalate synthesis to serve as a platform to develop novel... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
05/13/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Kidney Stone
Register for Updates
Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist
NCT06851858
Recruiting
This Phase II study is a randomized, parallel group, double blinded, placebo-controlled, multicenter to evaluate the efficacy, safety, and tolerability of AZD6234 in adults with overweight or obesity and type 2 diabetes on stable GLP-1 RA therapy.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/12/2025
Locations: Research Site, Birmingham, Alabama
Conditions: Endocrinology, Diabetes, Type II, Obesity
Register for Updates
A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension
NCT06785454
Recruiting
The primary purpose of the study is to assess the effect of lorundrostat taken orally (po) once a day on the Apnea-Hypopnea Index (AHI) in participants with moderate to severe obstructive sleep apnea (OSA) and hypertension.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/12/2025
Locations: The University of Alabama, Tuscaloosa, Alabama
Conditions: Obstructive Sleep Apnea, Hypertension
Register for Updates
Efficacy and Safety of Gemlapodect (NOE-105) in Adults and Adolescents With Tourette Syndrome
NCT06315751
Recruiting
This study is designed to evaluate the efficacy and safety of gemlapodect (NOE-105) on reducing tics associated with Tourette Syndrome (TS) in adults with TS. Adolescents will be enrolled after a sentinel cohort of adults is complete.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: NOE-TTS-201 Site #63, Dothan, Alabama
Conditions: Tourette Syndrome
Register for Updates
A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA)
NCT06240351
Recruiting
The goal of this clinical trial is to evaluate the safety and efficacy of Baricitinib in the treatment of frontal fibrosing alopecia (FFA).
Gender:
FEMALE
Ages:
Between 18 years and 90 years
Trial Updated:
05/12/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Frontal Fibrosing Alopecia
Register for Updates
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery
NCT06161441
Recruiting
This study is researching an experimental drug called fianlimab (also called REGN3767) with two other medications called cemiplimab and platinum-doublet chemotherapy, individually called a "study drug" or collectively called "study drugs", when combined in this study. The study is being conducted in patients who have resectable stage II to IIIB (N2) non-small cell lung cancer (NSCLC) that can be treated with surgery. The aim of the study is to see how effective the combination of fianlimab, cem... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Resectable Non-small Cell Lung Cancer
Register for Updates
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy
NCT06063850
Recruiting
The main goals of this clinical study are to learn if AMT-260 is safe and tolerable and works to reduce the frequency of seizures in adults with unilateral mesial temporal lobe epilepsy (MTLE).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/12/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Mesial Temporal Lobe Epilepsy
Register for Updates